至2040年2型糖尿病相关终末期肾病发病率预测:糖尿病预防与治疗效果的比较
该研究利用生命表模型预测澳大利亚至2040年2型糖尿病相关终末期肾病(ESKD-D)的发病率。若维持当前趋势,年发病率将从2014年的3.7/10万升至2040年的5.7/10万;糖尿病预防措施仅降至5.2–5.5/10万,而50%和70%合格患者使用SGLT2抑制剂可分别降至4.7和4.3/10万。2020–2040年间,SGLT2抑制剂减少ESKD-D病例12–21%,糖尿病预防仅减少1–3%。
要点
- 维持现有趋势,ESKD-D年发病率至2040年将增至5.7/10万。
- SGLT2抑制剂广泛使用可显著降低ESKD-D发病率及病例数。
- 糖尿病预防对减少ESKD-D病例作用有限,但可控制并发症负担。
核心结论
- 预计未来数十年ESKD-D发病人数将增加。
- 广泛使用SGLT2抑制剂可有效遏制该增长。
- 糖尿病预防对防止糖尿病并发症负担持续增加至关重要。
研究设计与样本
- 研究采用生命表模型,预测澳大利亚2型糖尿病相关ESKD-D发病率至2040年。
- 模型设定三种情景:大规模生活方式干预预防糖尿病、人群含糖饮料税预防糖尿病、糖尿病患者广泛使用SGLT2抑制剂。
主要发现
- 当前趋势下,ESKD-D年发病率从2014年3.7/10万升至2040年5.7/10万。
- 糖尿病预防情景下,2040年年发病率预计为5.2–5.5/10万。
- 50%和70%合格患者使用SGLT2抑制剂时,2040年年发病率分别降至4.7和4.3/10万。
- 2020–2040年,SGLT2抑制剂减少ESKD-D病例12–21%,糖尿病预防减少1–3%。
临床怎么用
- 应重视SGLT2抑制剂在糖尿病患者中的广泛使用以降低ESKD-D风险。
- 糖尿病预防策略仍需持续推进以控制并发症总体负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study sought to examine the effects of two diabetes prevention approaches and of widespread use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) among people with diabetes on the future incidence of diabetes-related end-stage kidney disease (ESKD-D). RESEARCH DESIGN AND METHODS: We developed a life table model to project the incidence of ESKD-D for type 2 diabetes in Australia until 2040. We projected incident ESKD-D under three separate scenarios: a large-scale lifestyle modification program for diabetes prevention; a population-wide sugar-sweetened beverage tax for diabetes prevention; and widespread use of SGLT2is among people with diabetes. RESULTS: Assuming current trends, we projected that the annual incidence of ESKD-D will increase from 3.7 per 100,000 of the general population in 2014 to 5.7 by 2040. Incorporating the diabetes prevention approaches, we projected that the annual incidence of ESKD-D will be between 5.2 and 5.5 per 100,000 by 2040. When we modeled scenarios in which 50% and 70% of eligible people with diabetes were prescribed an SGLT2i, the annual incidence of ESKD-D by 2040 was projected to be 4.7 and 4.3 per 100,000, respectively. SGLT2is were projected to reduce the total number of incident ESKD-D cases between 2020 and 2040 by 12-21% compared with current trends, whereas diabetes prevention reduced cases by 1-3%. CONCLUSIONS: It is likely that the number of people developing ESKD-D will increase over the coming decades, although widespread SGLT2i use will be effective at limiting this increase. Diabetes prevention will be crucial to prevent an ever-increasing burden of diabetes complications.
引用
- Morton JI, McDonald SP, Salim A, et al. Projecting the Incidence of Type 2 Diabetes-Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Diabetes Care. 2021. PMID: 34024758. doi:10.2337/dc21-0220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。